Compare Gilead Sciences, Inc. (GILD) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Samsara Inc — how do they compare? Gilead Sciences, Inc. trades at $133.2 (market cap $163.51B), while Samsara Inc trades at $36.41 (market cap $21.23B). The key difference: Gilead Sciences, Inc. is far larger — about 7.7× Samsara Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Samsara Inc pays none. Which is the better fit depends on your goals.
| GILD | IOT | |
|---|---|---|
Market Cap | $163.51B | $21.23B |
Sector | Health | Technology |
52-Week High | $155.80 | $45.22 |
52-Week Low | $108.22 | $24.25 |
Enterprise Value | $178.05B | $20.49B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Samsara (IOT) trades at $35.91, down 2.7% today but showing strong technical momentum with bullish moving averages and RSI signals. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $0.17. Revenue grew from $1.25B in 2025 to a projected $1.7B in 2026, turning net income positive. Recent news highlights product launches including AI tools and tracking labels to enhance operational visibility.
Outlook remains positive with a $44.40 analyst price target implying 24% upside. Key opportunities include sustained earnings beats and expanding gross margins of 76.25%. Risks involve high P/E of 364.3 and negative cash flow projection for 2026. Institutional sentiment is bullish with 78% buy ratings, though valuation sensitivity persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
